Debevoise Advises Konica Minolta in the $600 Million Sale of Ambry to Tempus AI
November 06, 2024
November 06, 2024
NEW YORK, Nov. 6 -- Debevoise and Plimpton, a law firm, issued the following news:
Debevoise & Plimpton LLP is advising Konica Minolta in the sale of its subsidiary, Ambry Genetics, to Tempus AI (NASDAQ: TEM) in which Tempus will acquire Ambry for $375 million in cash and $225 million in shares at closing, of which $100 million will be subject to a lock-up agreement until one year post-transaction close.
For more information, please see the company's press release.< . . .
Debevoise & Plimpton LLP is advising Konica Minolta in the sale of its subsidiary, Ambry Genetics, to Tempus AI (NASDAQ: TEM) in which Tempus will acquire Ambry for $375 million in cash and $225 million in shares at closing, of which $100 million will be subject to a lock-up agreement until one year post-transaction close.
For more information, please see the company's press release.< . . .